Protalix BioTherapeutics Issues 2025 Letter to Stockholders - Stock Titan
Protalix BioTherapeutics, Inc. shares accomplishments in 2024, including EMA validation for pegunigalsidase alfa dosing, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 and pipeline developments in 2025.
Highlighted Terms
Elelyso®Protalix BioTherapeuticsPfizer Inc.European Medicine AgencyPRX–119Fabry diseaseNETs-related diseasespegunigalsidase alfaFundação Oswaldo CruzElfabrio®PRX 115Brazilian Ministry of HealthChiesi Global Rare Diseasesuncontrolled goutLifeSci AdvisorsAmerican College of RheumatologyUplyso®Chiesi Farmaceutici S.p.A.U.S. Securities and Exchange Commission
Related News
Protalix BioTherapeutics Issues 2025 Letter to Stockholders - Stock Titan
Protalix BioTherapeutics, Inc. shares accomplishments in 2024, including EMA validation for pegunigalsidase alfa dosing, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 and pipeline developments in 2025.